FOSAPREPITANT DIMEGLUMINE

Post-LOE

fosaprepitant

Viatris (2)

ANDAINTRAVENOUSPOWDER

Approved

Sep 2019

Lifecycle

Post-LOE

Competitive Pressure

30/100

Clinical Trials

Data completeness

4/8 — Partial

FOSAPREPITANT DIMEGLUMINE (fosaprepitant) by Viatris (2) is accordingly, its antiemetic effects are attributable to aprepitant. Approved for delayed nausea, vomiting associated with initial, repeat courses of highly emetogenic cancer chemotherapy (hec) including high-dose cisplatin and 1 more indications. First approved in 2019.

Drug data last refreshed 19h ago

Mechanism of Action

accordingly, its antiemetic effects are attributable to aprepitant. Aprepitant is a selective high-affinity antagonist of human substance P/neurokinin 1 (NK 1 ) receptors. Aprepitant has little or no affinity for serotonin (5-HT 3 ), dopamine, and corticosteroid receptors, the targets of existing…

Indications (4)

delayed nausea vomiting associated with initial

Worked on FOSAPREPITANT DIMEGLUMINE at Viatris (2)? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Clinical Trials (16)

NCT04054193Phase 4Completed

Safety of a Three-Day Fosaprepitant Regimen for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Pediatric Participants (MK-0517-045)

Started Sep 2019

103 enrolled

Chemotherapy-induced Nausea and Vomiting

NCT03578081Phase 3Completed

Olanzapine With or Without Fosaprepitant Dimeglumine in Preventing Chemotherapy Induced Nausea and Vomiting in Cancer Patients Receiving Highly Emetogenic Chemotherapy

Started Nov 2018

690 enrolled

Malignant Neoplasm

NCT02519842Phase 3Terminated

Efficacy and Safety Study of Fosaprepitant (MK-0517) Plus Ondansetron Versus Ondansetron Alone for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Pediatric Participants (MK-0517-044)

Started Sep 2015

75 enrolled

Chemotherapy-induced Nausea and Vomiting

NCT02407600Phase 2Unknown

Study Assessing Fosaprepitant in Advanced NSCLC Patients Treated With Carboplatin Based Chemotherapy

Started Apr 2015

150 enrolled

Non-small Cell Lung CancerVomitingNausea+1 more

NCT01874119Phase 2Terminated

Fosaprepitant for N/V With High-dose Interleukin-2 for Metastatic Melanoma and Renal Cell Carcinoma

Started Sep 2013

13 enrolled

Chemotherapy-induced Nausea and Vomiting